Published in Gene Therapy Weekly, July 28th, 2005
In 3 out of 19 patients harboring BCR-ABL mutations, the mutations were detectable 1-2 months from the onset of therapy only by denaturing HPLC performed with the Wave system, but were not detectable by direct DNA sequencing. Since all but 4 patients with mutations had sustained hematologic responses to imatinib at the time of mutation detection, early mutation screening may identify patients at risk...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.